Inherited kidney disorder
MONDO:0100191A heterogeneous group of genetic conditions, with Mendelian (autosomal dominant, recessive, or X-linked) or chromosomal etiology that are characterized by abnormalities in the kidney or urinary system.
Also known as: genetic renal disease, inherited kidney disease, inherited renal disorder, nephrogenetic disorder
291 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to slow kidney failure in rare genetic disease
Disease control Recruiting nowThis study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults will receive either …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Gene therapy breakthrough targets kidney disease in High-Risk patients
Disease control Recruiting nowThis study tests a new gene therapy, PS-002, for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The therapy aims to control the disease in people who are at high risk of getting worse despite current treatments. Participants receive a single dose a…
Phase: PHASE1, PHASE2 • Sponsor: Purespring Therapeutics Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to calm immune attacks on kidneys
Disease control Recruiting nowThis Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immune cell therapy takes on kidney disease
Disease control Recruiting nowThis early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tame rare kidney diseases
Disease control Recruiting nowThis Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New kidney drug shows promise in reducing protein leakage
Disease control Recruiting nowThis study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cells tailored to attack lung cancer show promise in early trial
Disease control Recruiting nowThis trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug zigakibart aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug BHV-1400 tested for kidney disease
Disease control Recruiting nowThis early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Recruiting nowThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Single-Port robot could make pediatric surgery less invasive
Disease control Recruiting nowThis trial tests whether a new robotic system that uses only one small incision (single port) can safely perform common abdominal surgeries in children. The study includes children aged 1 to 17 who need procedures like pyeloplasty or reflux treatment. The goal is to see if the si…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a diabetes drug protect kidneys in polycystic disease? new trial aims to find out
Disease control Recruiting nowThis phase 3 trial tests whether the drug dapagliflozin can slow the loss of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD), a common genetic cause of kidney failure. The study will enroll 420 people aged 18 to 60 with rapid disease progressio…
Phase: PHASE3 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slow kidney failure in IgA nephropathy patients
Disease control Recruiting nowThis phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets genetic form of polycystic kidney disease
Disease control Recruiting nowThis study tests an experimental drug called VX-407 in 24 adults with autosomal dominant polycystic kidney disease (ADPKD) who have specific changes in the PKD1 gene. The goal is to see if the drug can slow kidney growth and is safe. Participants take VX-407 tablets by mouth and …
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney disease: first human trial of PYC-003 begins
Disease control Recruiting nowThis study is the first time a new drug called PYC-003 is being tested in humans. It is for people with a genetic kidney disease that causes cysts to grow and damage the kidneys. The trial will first test the drug in healthy volunteers to check safety, then in patients with the d…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Parkinson's drug repurposed to fight kidney disease?
Disease control Recruiting nowThis study tests whether a rotigotine skin patch, a drug used for Parkinson's disease, is safe for people with autosomal dominant polycystic kidney disease (ADPKD). ADPKD causes fluid-filled cysts in the kidneys and can lead to kidney failure. The trial will give 120 adults eithe…
Phase: PHASE2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for advanced kidney cancer: first human trial of NEO-811 begins
Disease control Recruiting nowThis early-stage study tests a new drug called NEO-811 in people with advanced clear cell kidney cancer that has spread or cannot be surgically removed. The goal is to find the safest dose and see how well the drug works. About 30 participants who have already tried other treatme…
Phase: PHASE1 • Sponsor: Neomorph, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with kidney disease: experimental drug aims to cut protein leak
Disease control Recruiting nowThis study tests an experimental drug called iptacopan in 31 children aged 2 to under 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety and how t…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kidney disease: Zigakibart's Long-Term safety under study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can a lupus drug protect kidneys in IgA disease? new trial aims to find out.
Disease control Recruiting nowThis study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloro…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug shows promise for kidney disease patients
Disease control Recruiting nowThis study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damag…
Phase: PHASE2 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare kidney disease: iptacopan trial aims to protect kidneys
Disease control Recruiting nowThis study tests a drug called iptacopan in people with a rare kidney disease (IC-MPGN). About 106 adults and teens will receive either iptacopan or a placebo. The main goal is to see if iptacopan reduces protein in the urine and helps preserve kidney function over 18 months.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill aims to tame kidney disease in Long-Term trial
Disease control Recruiting nowThis study tests a new tablet called HSK39297 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The trial includes 73 adults who have already taken the drug in a previous study. They will take the tablet once daily for an extended period, with a p…
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill aims to plug protein leak in kidney patients
Disease control Recruiting nowThis study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein leve…
Phase: PHASE2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kidney disease: JADE101 trial launches
Disease control Recruiting nowThis study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…
Phase: PHASE2 • Sponsor: Jade Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a gut bug beat kidney stones?
Disease control Recruiting nowThis study tests whether giving people a live gut bacterium called Oxalobacter formigenes can lower the amount of oxalate in their urine. High urinary oxalate is a major risk factor for calcium oxalate kidney stones. Forty adults with a history of such stones who lack this bacter…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental tablet called HSK39297 in 370 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and slow down kidney function decline over 36 to 48 weeks. Participants will be randomly assigned to receiv…
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug aims to shrink cysts in genetic kidney disease
Disease control Recruiting nowThis study tests an investigational drug called ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys. About 240 participants worldwide will receive either the drug or a placebo …
Phase: PHASE2 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Keto diet tested as a way to delay kidney failure
Disease control Recruiting nowThis study looks at whether a well-formulated ketogenic diet can delay the progression of polycystic kidney disease in 20 adults who are at high risk for kidney failure. Participants will follow the diet for one year and have regular blood tests, urine tests, and MRI scans to tra…
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to shield kidneys in IgA disease
Disease control Recruiting nowThis study tests whether adding budesonide capsules early to standard blood-pressure and sugar-lowering drugs can reduce protein in the urine of people with IgA nephropathy, a kidney disease. Thirty adults with newly diagnosed disease will take the combination for 9 months, then …
Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis Phase 2 trial tests an investigational drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease. Participants receive either a high, medium, or low dose of SHR-2173 or a placebo for 48 weeks. The main goal is to see if the drug reduces protein in the …
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug AZD1613 tested for safety in kidney disease patients
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called AZD1613 in 40 adults with autosomal dominant polycystic kidney disease (ADPKD), a condition that causes kidney cysts. Participants receive either the drug or a placebo to check for side effects and how the drug moves th…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for kids with rare kidney diseases: drug trial aims to cut protein leak
Disease control Recruiting nowThis study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug YKST02 aims to tame kidney disease in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug is safe and tolerable, and to check if it reduces protein in the urine, a sign of kidney damage. Particip…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a phone app slow kidney disease? new trial aims to find out
Disease control Recruiting nowThis study tests whether a smartphone app can help people with chronic kidney disease (CKD) follow the latest KDIGO treatment guidelines. Researchers will enroll 80 adults aged 16-30 with CKD who own a smartphone. The app provides reminders, education, and care recommendations to…
Phase: NA • Sponsor: St. James's Hospital, Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug aims to halt kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests iptacopan, an oral drug, in 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to see if the drug reduces signs of inflammation and damage over 9 months. The goal is to understand if iptacopan can slow disease pro…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for dialysis patients: non-surgical kidney reduction could clear the way for transplant
Disease control Recruiting nowThis study looks at a non-surgical procedure called renal embolization to shrink enlarged kidneys in 30 dialysis patients with autosomal dominant polycystic kidney disease (ADPKD). The goal is to reduce kidney size enough to make a future kidney transplant possible and improve co…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for rare kidney patients: Long-Term drug trial shows promise
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New antibody drug aims to control kidney disease
Disease control Recruiting nowThis study tests a new drug called MIL116 in healthy volunteers and people with IgA nephropathy, a kidney disease. The drug is given as a shot under the skin and aims to reduce harmful antibodies that damage the kidneys. The study checks for safety, side effects, and how well the…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to slow kidney damage in diabetes and rare diseases
Disease control Recruiting nowThis study tests an experimental drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic nephropathy and several rare conditions. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, th…
Phase: PHASE2 • Sponsor: Walden Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. …
Phase: PHASE1 • Sponsor: DeuterOncology • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug metformin tested as new weapon against kidney disease
Disease control Recruiting nowThis study tests whether metformin, a drug used for diabetes, can slow the loss of kidney function in people with early-stage autosomal dominant polycystic kidney disease (ADPKD). About 1,174 adults aged 18-70 with mild to moderate kidney decline will take metformin or a placebo …
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a keto diet help slow kidney disease? new study seeks answers
Disease control Recruiting nowThis study tests a 16-week nutritionist-led ketogenic diet program (Ren-Nu) with a medical food called KetoCitra in 20 adults with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if the diet can improve kidney function and other health markers while monit…
Phase: NA • Sponsor: Richard Fatica • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Water pill could boost kidney Drug's power and cut side effects
Disease control Recruiting nowThis study tests whether adding a common water pill (hydrochlorothiazide) to the standard drug tolvaptan can slow kidney function decline and reduce side effects like frequent urination in people with autosomal dominant polycystic kidney disease (ADPKD). About 300 adults on a sta…
Phase: PHASE3 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Hope for kids with rare kidney disease: drug trial aims to slow damage
Disease control Recruiting nowThis trial tests the safety of tolvaptan, a drug that helps the body remove extra water, in 20 children aged 28 days to 18 years with autosomal recessive polycystic kidney disease (ARPKD). The goal is to see if the drug can slow kidney function decline and reduce the need for dia…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Hope for hypothalamic obesity: daily shot targets weight and hunger
Disease control Recruiting nowThis phase 3 trial tests whether a daily injection of setmelanotide can help people aged 4 and older with hypothalamic obesity lose weight and feel less hungry. Participants will receive either the drug or a placebo for 26 weeks. The study aims to see if the treatment leads to me…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a longer course of TARPEYO tame kidney disease?
Disease control Recruiting nowThis study looks at whether taking TARPEYO (budesonide) for a longer period helps adults with IgA nephropathy, a kidney disease. Participants have already taken the drug for 9 months and will now take it for another 15 months. The main goal is to see if protein levels in urine st…
Phase: PHASE4 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on kidney disease in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new treatment for children with B cell-related autoimmune diseases like lupus and kidney disease. The therapy uses specially engineered natural killer (NK) cells that target and destroy faulty immune cells. Only 12 children will take part, and …
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill aims to tame high uric acid in kidney patients
Disease control Recruiting nowThis study tests an experimental drug called IG3018 for people with high uric acid, some of whom also have chronic kidney disease. About 60 adults will receive either the drug or a placebo for 4 weeks. Researchers will check safety, side effects, and how well the drug lowers uric…
Phase: PHASE1, PHASE2 • Sponsor: Intelligem Therapeutics Australia Pty Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kidney disease patients: managed access to EXV811, atrasentan
Disease control AVAILABLEThis program provides access to EXV811, atrasentan for people with IgA nephropathy, a serious kidney disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for kidney patients: early budesonide may slow IgA nephropathy
Disease control Recruiting nowThis study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults with recent diagnosis and high protein in urine will take the drug for 12 months. Researchers will measure changes in protein levels and kidney fun…
Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New injection aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug safely reduces protein in urine, a sign of kidney damage. Participants receive either the drug or a placebo, and neither they nor their doct…
Phase: PHASE2 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new type of cell therapy (CAR-NK cells) in 36 children with B-cell-related autoimmune diseases like lupus and certain kidney diseases. The therapy uses specially designed immune cells to target and potentially control the overactive immune syst…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Diabetes drug shows promise for dangerous low sodium condition
Disease control Recruiting nowThis study tests whether the diabetes drug empagliflozin (Jardiance) can safely raise low sodium levels in people with certain conditions like SIADH, liver failure, or kidney failure. About 172 adults with chronic low sodium will receive either the drug or a placebo for up to 30 …
Phase: PHASE4 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New fetal procedure aims to save babies with rare bladder blockage
Disease control Recruiting nowThis study tests a step-by-step treatment plan for fetuses with lower urinary tract obstruction (LUTO), a condition where a blockage prevents urine from leaving the bladder. Doctors will use either a shunt to drain urine or a tiny scope to clear the blockage. The goal is to see i…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Womb fluid injections could give babies with no kidneys a chance to breathe
Disease control Recruiting nowThis study tests whether repeatedly injecting a sterile saltwater solution into the womb can help fetuses with severe kidney problems grow their lungs. Normally, these babies have too little amniotic fluid, which prevents the lungs from developing. The goal is to see if this proc…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a One-Size-Fits-All pill beat kidney stones?
Disease control Recruiting nowThis study is testing whether a simple, standard prevention plan works as well as a personalized one for people who get calcium oxalate kidney stones. 80 participants will either receive a diuretic and diet advice based on their stone type alone, or have their treatment guided by…
Phase: PHASE4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo aims to tame rare kidney disease
Disease control Recruiting nowThis phase 2 trial tests whether adding avacopan (a pill that blocks inflammation) to low-dose steroids can help people with crescentic IgA nephropathy, a severe kidney condition. Sixteen adults with high-risk features will be randomly assigned to receive either avacopan plus low…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug hope for rare kidney disease: daratumumab trial launches
Disease control Recruiting nowThis study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 18:10 UTC
-
New drug cocktail aims to slow kidney disease in IgA patients
Disease control Recruiting nowThis study tests whether combining budesonide (Nefecon) and ambrisentan can reduce protein in the urine and preserve kidney function in people with IgA nephropathy who are at risk of kidney failure. About 129 adults will take both pills daily for 36 weeks. Researchers will measur…
Phase: PHASE4 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC
-
New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control Recruiting nowThis study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…
Phase: PHASE2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC
-
New test could make diagnosis of thirst disorders easier for patients
Diagnosis Recruiting nowThis study compares a new diagnostic test using mannitol infusion to the standard hypertonic saline test for diagnosing the cause of polyuria-polydipsia syndrome (excessive urination and thirst). Researchers will enroll 144 adults to see if the mannitol test is as accurate and mo…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Hormone pill could unlock diagnosis of rare oxytocin deficiency in teens
Diagnosis Recruiting nowThis early-phase trial is testing whether a single dose of a hormone pill can help diagnose oxytocin deficiency in young people with hypopituitarism. Researchers will give the pill to 20 participants and measure oxytocin-related substances in blood and saliva. The goal is to deve…
Phase: EARLY_PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Amniotic fluid test may predict kidney outcomes in unborn babies
Diagnosis Recruiting nowThis study aims to confirm if a test using a sample of amniotic fluid can accurately predict how well a baby's kidneys will work after birth. Researchers will analyze 78 fetuses with kidney and urinary tract malformations from hospitals across France. The goal is to see if this t…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Blood test could replace risky needle for prenatal genetic diagnosis
Diagnosis Recruiting nowThis study is testing a new blood test that can diagnose single-gene disorders in unborn babies using a sample from the mother. The test looks at fetal DNA found in the mother's blood, which is safer than traditional invasive methods that carry a small risk of miscarriage. Resear…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Could a new ultrasound replace radiation scans for Kids' kidney defects?
Diagnosis Recruiting nowThis study tests a new ultrasound technique that uses a contrast dye and special computer processing to create detailed images of blood flow and tiny blood vessels in the kidneys. It will involve 20 children aged 1 month to 6 years with congenital kidney and urinary tract abnorma…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Diagnosis
Last updated Jun 26, 2026 17:57 UTC
-
Cartoon characters could make Kids' eye exams more accurate
Diagnosis Recruiting nowThis study tests whether showing cartoon video clips and using character voices during a visual field test can help children aged 5-8 stay focused and give more reliable results. Twenty children with certain eye conditions will be tested twice, once with the cartoon intervention …
Phase: NA • Sponsor: Nova Southeastern University • Aim: Diagnosis
Last updated Jun 26, 2026 16:36 UTC
-
Could a common diabetes drug stop kidney stones before they start?
Prevention Recruiting nowThis study tests whether empagliflozin, a drug used for diabetes and heart conditions, can help prevent calcium-based kidney stones. Researchers will give the drug daily for 4 weeks to 32 adults who have had calcium oxalate or calcium phosphate stones. They will measure changes i…
Phase: EARLY_PHASE1 • Sponsor: University of Chicago • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
New study tests which nerve block eases kidney surgery pain best
Symptom relief Recruiting nowThis study compares two types of ultrasound-guided nerve blocks for pain control after open kidney removal surgery. Ninety adults will receive either a rhomboid intercostal sub-serratus plane block or an external oblique intercostal block. Researchers will measure how long it tak…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Splint or exercise? new study aims to settle best treatment for thumb tendonitis
Symptom relief Recruiting nowThis study compares two common conservative treatments for De Quervain's tenosynovitis, a painful thumb tendon condition: a static hand-wrist splint versus home-based exercise therapy. Forty adults with acute or subacute pain will be tracked for changes in pain, wrist function, a…
Phase: NA • Sponsor: Konya Beyhekim Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Let it fall? study tests if letting catheters drop out on their own is better than nurse removal
Symptom relief Recruiting nowThis study tests whether letting a bladder catheter fall out on its own (passive removal) is better than having a nurse pull it out (active removal) after urological surgery. 160 men will be randomly assigned to one method. Researchers will measure satisfaction, pain, and anxiety…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Spinal shot vs IV drip: which helps you recover faster from robotic surgery?
Symptom relief Recruiting nowThis Phase 3 trial tests whether a single spinal injection of morphine and bupivacaine before robotic kidney or ureter surgery leads to better recovery than an intravenous lidocaine drip during surgery. About 220 adults scheduled for robotic upper urinary tract surgery will be ra…
Phase: PHASE3 • Sponsor: Hans Bahlmann • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Foam injection may ease pain from polycystic kidney and liver cysts
Symptom relief Recruiting nowThis study looks at whether foam sclerotherapy can reduce pain and improve quality of life for people with autosomal dominant polycystic kidney or liver disease who have large, painful cysts. Researchers will treat 100 adults with 1-3 dominant cysts and follow them for 12 months.…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can a 'Love Hormone' spray boost sexual health in diabetes insipidus?
Symptom relief Recruiting nowThis phase 2 trial tests whether oxytocin nasal spray can improve sexual well-being in people with central diabetes insipidus, a condition that also causes oxytocin deficiency. The study includes 42 participants (patients and healthy controls) and uses a double-blind, placebo-con…
Phase: PHASE2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Could a nasal spray ease anxiety in a rare hormone disorder?
Symptom relief Recruiting nowThis pilot study is testing whether an oxytocin nasal spray can help with anxiety, depression, and social functioning in adults with arginine-vasopressin deficiency, a rare hormone disorder. In the first part, 30 participants will receive single doses of oxytocin or placebo and c…
Phase: PHASE1 • Sponsor: Elizabeth Austen Lawson • Aim: Symptom relief
Last updated Jun 26, 2026 18:16 UTC
-
Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
Knowledge-focused Recruiting nowThis study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study uses motion capture to understand balance problems in MS
Knowledge-focused Recruiting nowThis study is observing 40 adults with multiple sclerosis to see how clinical tests of balance and walking relate to detailed motion-capture measurements. Participants will attend one session where they walk on force plates and perform balance tasks while cameras track their move…
Sponsor: University of Patras • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
800-Patient study aims to uncover best treatments for kidney disease
Knowledge-focused Recruiting nowThis observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive study aims to unlock secrets of parathyroid diseases
Knowledge-focused Recruiting nowThis study follows up to 3,000 people who have, are at risk for, or are related to someone with a parathyroid disorder. Researchers will collect medical records, questionnaires, and samples like blood and saliva to learn what causes these conditions and how they change over time.…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New registry aims to unlock secrets of kidney disease that starts in childhood
Knowledge-focused Recruiting nowThis study creates a registry to collect health information from people with Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common genetic cause of kidney failure. While ADPKD was once thought to only affect adults, researchers now know it begins in childhood, but…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New registry aims to unlock secrets of rare Kidney-Liver diseases
Knowledge-focused Recruiting nowThis study is creating a central database and tissue bank for rare diseases affecting the kidneys and liver, such as ARPKD and Joubert syndrome. Researchers will collect medical information, genetic samples, and tissues from 200 participants to help doctors and scientists better …
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Personalized trial matching could revolutionize kidney disease treatment
Knowledge-focused Recruiting nowThis study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…
Phase: NA • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New ultrasound test may predict kidney healing in kids after surgery
Knowledge-focused Recruiting nowThis study looks at whether a special ultrasound technique, called shear wave elastography, can predict how well a child's kidney will recover after surgery to fix a blockage. Researchers will measure kidney stiffness before and after surgery in 84 children aged 6 months to 18 ye…
Sponsor: Beni-Suef University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists investigate if kidney stone sufferers produce excess oxalate
Knowledge-focused Recruiting nowThis study aims to find out if people who get calcium oxalate kidney stones produce more oxalate in their bodies than healthy people. Researchers will compare 80 adults—some with a history of stones and some without—after they eat a special low-oxalate diet and take small amounts…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Could your gut be the culprit behind kidney stones?
Knowledge-focused Recruiting nowThis study aims to find out if people who get calcium oxalate kidney stones absorb more oxalate from food than healthy people. Researchers will compare stone formers and healthy volunteers by having them eat special diets and measuring oxalate in urine, blood, and stool. The goal…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Scientists track families to unlock secrets of inherited kidney cancer
Knowledge-focused Recruiting nowThis study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Scientists investigate Oxalate's role in kidney stone development
Knowledge-focused Recruiting nowThis study aims to understand how oxalate, a substance found in many foods, contributes to kidney stone formation and affects the body's immune system. Researchers will enroll 88 healthy volunteers and people with calcium oxalate kidney stones. Participants will follow a controll…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Kidney disease drug under the microscope: how does tolvaptan really work?
Knowledge-focused Recruiting nowThis study is tracking up to 2,000 people with autosomal dominant polycystic kidney disease (ADPKD) who are taking or considering tolvaptan. Researchers will collect real-world data on dosing, side effects, and kidney function over time. The goal is to understand how the drug is …
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Scientists launch biobank to unlock secrets of early kidney disease
Knowledge-focused Recruiting nowThis observational study is collecting blood and urine samples from 250 people with early-stage polycystic kidney disease (PKD), their unaffected family members, and healthy volunteers. The goal is to create a biobank that researchers can use to find biological markers of disease…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Alport patients needed: join a registry to speed up research
Knowledge-focused Recruiting nowThis registry is for people in the US with Alport syndrome. It collects health information over time through a secure online portal. The goal is to gather real-world data to help researchers understand the disease better and design future clinical trials. No treatments or medicat…
Sponsor: Alport Syndrome Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists hunt for kidney stone genes in 6,000-Person study
Knowledge-focused Recruiting nowThis study aims to find the specific genes and mutations that cause rare, inherited forms of kidney stone disease. Researchers will analyze DNA from up to 6,000 participants to understand how these genetic changes lead to stones. The goal is to use this knowledge to develop bette…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
2000 patients join hunt for early warning signs of kidney failure
Knowledge-focused Recruiting nowThis study follows 2000 Chinese patients with IgA nephropathy who still have relatively good kidney function. Researchers will test their blood and urine for biomarkers that might predict if and when their kidney disease gets worse. No new treatment is being tested; the goal is t…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists hunt for hidden antibodies in Kids' kidney disease
Knowledge-focused Recruiting nowThis study is investigating whether certain autoantibodies, especially those targeting a protein called nephrin, play a role in nephrotic syndrome, a kidney condition that causes swelling and protein loss in urine. Researchers will analyze blood and kidney tissue from 50 children…
Phase: NA • Sponsor: Meyer Children's Hospital IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New pill CMS-D017 enters first human safety trials
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study aims to sharpen diagnosis of malnutrition and kidney disease in seniors
Knowledge-focused Recruiting nowThis study is for older adults, including those in the hospital or with low priority care needs. Researchers want to see if newer methods, like body scans and blood tests, can better detect malnutrition and kidney problems than current standard tests. The goal is to make diagnosi…
Sponsor: Ove Andersen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Skin biopsies could unlock hidden genetic diagnoses
Knowledge-focused Recruiting nowThis study aims to improve diagnosis for people with rare genetic diseases whose standard genetic tests came back negative. Researchers will take a small skin sample and analyze RNA to find hidden genetic changes. The study involves 105 participants, including healthy volunteers …
Phase: NA • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Breathing easy under fire: heliox may boost warfighter brainpower
Knowledge-focused Recruiting nowThis study looks at whether breathing a lighter gas mixture (heliox) can make it easier to breathe and think clearly when breathing is hard. Fifteen healthy adults will breathe normal air or heliox while doing thinking tests. The goal is to see if reducing the work of breathing i…
Phase: PHASE4 • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New drug CLYM116 enters first human safety trial
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug, CLYM116, in 48 healthy adults aged 18-60. Participants receive either the drug or a placebo by injection, and researchers monitor for side effects and how the drug moves through the body. The study is not designed to treat an…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Blood marker may predict brain surgery complication in kids
Knowledge-focused Recruiting nowThis study looks at whether measuring a substance called copeptin in the blood can help doctors diagnose central diabetes insipidus (CDI) in children after brain surgery. CDI causes extreme thirst and frequent urination due to a hormone imbalance. The study will track copeptin le…
Sponsor: Children's Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
2000-Patient study aims to uncover hidden metabolic risks in rare genetic disorders
Knowledge-focused Recruiting nowThis observational study will follow 2000 children and adults with imprinting disorders—rare genetic conditions like Silver-Russell and Prader-Willi syndromes. Researchers aim to describe the natural history of these diseases and identify common metabolic profiles, risks for obes…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Music tweaked by tech may raise 'Love Hormone' levels
Knowledge-focused Recruiting nowThis study tests whether music enhanced with sonic augmentation technology can increase oxytocin (a hormone linked to social bonding) with few side effects. Researchers will compare the modified music to regular music in 22 healthy adults and patients with AVP-deficiency. The goa…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Can videos and quizzes help patients better understand surgery?
Knowledge-focused Recruiting nowThis study tests a new method to help patients understand complex spine or prostate surgeries before they agree to them. Instead of just reading a form, patients watch multimedia content and answer questions to check their understanding. The goal is to see if this approach makes …
Phase: NA • Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can AI match doctors? new study puts ChatGPT to the test on urology cases
Knowledge-focused Recruiting nowThis study looks at how well three AI models—ChatGPT, Gemini, and Deepseek—can diagnose and suggest treatments for urology diseases. Researchers will use 800 past patient records from four hospitals to check the AI's accuracy and usefulness. The goal is to understand if AI can he…
Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Could a simple estrogen pill reveal hidden oxytocin deficiency?
Knowledge-focused Recruiting nowThis study is testing whether taking estrogen pills (estradiol valerate or ethinylestradiol) can safely trigger the release of oxytocin, a hormone important for social bonding and childbirth. Researchers will measure oxytocin levels in 28 healthy volunteers and patients with AVP …
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New study seeks clues to kidney disease in young adults
Knowledge-focused Recruiting nowThis study aims to understand how oxidative stress and the body's antioxidant defenses work in early stages of autosomal dominant polycystic kidney disease (ADPKD). Researchers will measure various biomarkers in blood and urine, and use MRI to measure kidney size. The goal is to …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New biomarker study aims to track kidney disease severity
Knowledge-focused Recruiting nowThis study is looking for markers in urine and blood that can show how severe autosomal dominant polycystic kidney disease (ADPKD) is in its early stages. Researchers will measure NOX4, mitochondrial DNA, and other substances in 60 people aged 15-40 with early ADPKD. The goal is …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Blood test could replace kidney biopsy for common kidney disease?
Knowledge-focused Recruiting nowThis study looks at blood and kidney tissue from 150 adults with IgA nephropathy or related kidney diseases. Researchers want to find unique patterns in immune cells that cause kidney damage. The goal is to develop a blood test that could diagnose the disease without a painful ki…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Citrate study seeks to unlock kidney stone mysteries
Knowledge-focused Recruiting nowThis study looks at how two natural compounds in food, oxalate and citrate, interact in the body and affect kidney stone formation. Researchers will measure changes in urine levels of these compounds after participants consume potassium citrate. The study includes 24 adults, some…
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Can MRI and genes predict high blood pressure in kids with kidney disease risk?
Knowledge-focused Recruiting nowThis study aims to find out how common high blood pressure is in children and teenagers (ages 12-17) who are at risk for autosomal dominant polycystic kidney disease (ADPKD) because a parent has it. Researchers will use MRI scans and genetic tests to detect early signs of the dis…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New MRI methods could unlock ARPKD treatment trials
Knowledge-focused Recruiting nowThis study aims to develop better MRI-based tools to measure kidney disease progression in people with Autosomal Recessive Polycystic Kidney Disease (ARPKD), a serious genetic condition with no approved treatments. Researchers will enroll 45 ARPKD patients and 15 healthy voluntee…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New study aims to decode pain in kidney disease patients
Knowledge-focused Recruiting nowThis study looks at pain in people with ADPKD, a kidney disease that often causes pain in the belly, side, and back. Researchers will use sensory tests and questionnaires to understand the pain better. They will compare results from 150 patients with those from healthy volunteers…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Massive PKD data collection aims to unlock secrets of kidney disease
Knowledge-focused Recruiting nowThis study is building a large database of health information from people with autosomal dominant polycystic kidney disease (PKD), the most common inherited kidney disease. Researchers will collect data from 1,000 adults over time to better understand complications like high bloo…
Sponsor: The Rogosin Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Sound waves may replace X-Rays for dental implant timing
Knowledge-focused Recruiting nowThis study at the University of Michigan is testing whether ultrasound can monitor bone graft healing after tooth extraction, potentially replacing more invasive scans. About 140 adults needing a tooth extraction and bone graft for a future dental implant will have their healing …
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New registry aims to unlock secrets of Ultra-Rare SPLIS disease
Knowledge-focused Recruiting nowThis study collects medical and genetic information from people with SPLIS, a rare condition caused by a faulty enzyme. Researchers will track survival and when kidney problems start. No treatments are given, but the registry may help future research.
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Massive european study aims to unlock secrets of rare kidney disease
Knowledge-focused Recruiting nowThis study follows 700 people with Alport syndrome, a rare inherited disease that can lead to kidney failure, hearing loss, and eye problems. Researchers will collect health data and samples over time to map how the disease progresses and to find early markers of kidney decline. …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC
-
Diabetes drug empagliflozin studied for kidney disease mineral effects
Knowledge-focused Recruiting nowThis phase 2 trial is testing whether the diabetes drug empagliflozin changes how the kidneys handle calcium, phosphate, and magnesium in people with autosomal dominant polycystic kidney disease (ADPKD). Forty adults will take either empagliflozin or a placebo for two weeks, then…
Phase: PHASE2 • Sponsor: Cantonal Hospital Graubuenden • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:19 UTC
-
New registry aims to speed up PKD research
Knowledge-focused Recruiting nowThis study is creating a registry and biobank of 350 adults with autosomal dominant polycystic kidney disease (ADPKD) in the Mid-Atlantic region. Participants will provide medical information, have kidney volume measured by MRI, and donate blood, urine, and DNA samples. The goal …
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:39 UTC
-
Scientists hunt for drug targets in rare kidney disorder
Knowledge-focused Recruiting nowThis study looks at the genetic causes of nephronophthisis, a rare kidney disease that leads to kidney failure before age 20. Researchers will collect urine and blood samples from 310 patients and healthy relatives to study cells and identify potential drug targets. The goal is t…
Phase: NA • Sponsor: Imagine Institute • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:13 UTC
-
Scientists launch major study to unravel mysterious metabolism disorders
Knowledge-focused Recruiting nowThis study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:34 UTC